Product Information
GLIPIZIDE ER 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0737 per EA under NDC 64980028001. Its NADAC has been published 478 times since Aug 9, 2017.
FDA first approved this application on Dec 29, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980028001
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GLIPIZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA204720FDA Approved
12/29/2016
TE Code
AB
On Market Since
4/24/2017
Pharmacological Classes
Price Statistics
The NADAC for GLIPIZIDE ER 5 MG TABLET has been published 478 times since Aug 9, 2017, and over the history we have for it it has declined 50.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0737 per EA |
|---|---|
| All-time high | $0.1557 (Mar 14, 2018) |
| All-time low | $0.0707 (May 22, 2024) |
| 52-week high | $0.0835 |
| 52-week low | $0.0727 |
| Median price | $0.1056 |
| Average price | $0.1088 |
| Largest weekly change | +24.3% (Jun 19, 2024) |
| Weeks tracked | 478 |
| Tracking since | Aug 9, 2017 |
Generic Alternatives
The matcher finds 12 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 54% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glipizide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sulfonylurea class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLIPIZIDE ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLIPIZIDE ER 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0737 per EA (NDC 64980028001), effective Sep 30, 2026.
How has the price of GLIPIZIDE ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLIPIZIDE ER 5 MG TABLET has declined 50.2%. It has been tracked across 478 weekly CMS publications since Aug 9, 2017.
What are the highest and lowest recorded NADAC prices for GLIPIZIDE ER 5 MG TABLET?
Since Aug 9, 2017, the NADAC for GLIPIZIDE ER 5 MG TABLET has ranged from a low of $0.0707 (May 22, 2024) to a high of $0.1557 (Mar 14, 2018), with a median of $0.1056 per EA.
Are there cheaper alternatives to GLIPIZIDE ER 5 MG TABLET?
Yes. 12 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GLIPIZIDE 5 MG TABLET, is $0.0339 per EA — about 54% below GLIPIZIDE ER 5 MG TABLET.
Who manufactures GLIPIZIDE ER 5 MG TABLET?
GLIPIZIDE ER 5 MG TABLET (NDC 64980028001) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.